

# Fast Facts

NOVEMBER SPECIAL EDITION 2020

News for Providers from HealthPartners Professional Services and Hospital Network Management

## Administrative

### 3M Employer Plan Specialty Drug Update

HealthPartners administers the 3M employer plan in Minnesota and western Wisconsin. Starting 1/1/2021, 3M will be moving their specialty drug administration to Archimedes Rx. This change will affect 3M employees and dependents that receive specialty drugs covered through their pharmacy benefit and some specialty drugs that are professionally administered and reimbursed through their medical benefit.

Starting 1/1/2021, authorizations for these medications will be required through Archimedes Rx, not HealthPartners. If you submit an authorization request through HealthPartners, you will be redirected to Archimedes. This change does not affect any medications administered in the hospital inpatient setting. **This benefit change affects only 3M employees and dependents; no other HealthPartners members are affected by this change. The 3M Plan Group Number is 3190.**

Below is a list of the medical benefit, professional administered specialty medications that will require authorization through Archimedes. Questions can be directed to Archimedes Rx at **1-888-506-1180**. You can find information about Archimedes Rx at [archimedesrx.com](http://archimedesrx.com).

#### MEDICAL BENEFIT SPECIALTY DRUG LISTING:

HCPC Code	Generic Name	Brand Description
J0490	Belimumab	Benlysta
Q2044	Belimumab	Benlysta
C9249	Certolizumab Pegol	Cimzia
J0717	Certolizumab Pegol	Cimzia
J0718	Certolizumab Pegol	Cimzia
C9481	Reslizumab	Cinqair
J2786	Reslizumab	Cinqair
J3380	Vedolizumab	Entyvio
J0178	Aflibercept	Eylea
J0180	Agalsidase beta	Fabrazyme
C9466	Benralizumab	Fasenra
J0517	Benralizumab	Fasenra
J7317	Sodium Hyaluronate (Viscosupplement)	Hyalgan
J7319	Sodium Hyaluronate (Viscosupplement)	Hyalgan
J7321	Sodium Hyaluronate (Viscosupplement)	Hyalgan

**MEDICAL BENEFIT SPECIALTY DRUG LISTING (CONTINUED):**

<b>HCPC Code</b>	<b>Generic Name</b>	<b>Brand Description</b>
Q4083	Sodium Hyaluronate (Viscosupplement)	Hyalgan
J7322	Hyaluronan	Hymovis
Q5102	Infliximab-dyyb	Inflectra
Q5103	Infliximab-dyyb	Inflectra
J0202	Alemtuzumab (MS)	Lemtrada
J2778	Ranibizumab	Lucentis
J2503	Pegaptanib Sodium	Macugen
J1725	Hydroxyprogesterone Caproate	Makena
J1726	Hydroxyprogesterone Caproate	Makena
J1729	Hydroxyprogesterone Caproate	Makena
Q9885	Hydroxyprogesterone Caproate	Makena
Q9986	Hydroxyprogesterone Caproate	Makena
J7327	Hyaluronan	Monovisc
C9473	Mepolizumab	Nucala
J2182	Mepolizumab	Nucala
C9494	Ocrelizumab	Ocrevus
J2350	Ocrelizumab	Ocrevus
J7324	Hyaluronan	OrthoVisc
Q4086	Hyaluronan	OrthoVisc
C9493	Edaravone	Radicava
J1301	Edaravone	Radicava
Q3028	Interferon Beta-1a	Rebif
J1745	Infliximab	Remicade
Q5104	Infliximab-abda	Renflexis
C9489	Nusinersen	Spinraza
J2326	Nusinersen	Spinraza
J7325	Hylan	Synvisc
Q4084	Hylan	Synvisc
J7329	Sodium Hyaluronate (Viscosupplement)	TriVisc
J3396	Verteporfin	Visudyne
J0775	Collagenase Clostridium Histolyticum	Xiaflex
J2357	Omalizumab	Xolair

If you have questions regarding the content of this newsletter, please contact the person indicated in the article or call your HealthPartners Service Specialist. If you don't have his/her phone number, please call **952-883-5589** or toll-free at **888-638-6648**. This newsletter is available online at [healthpartners.com/fastfacts](http://healthpartners.com/fastfacts).

**Fast Facts Editors:** Mary Jones and David Ohmann